JANX fundamentals
Key facts
Market capitalization1.77 BUSD
Basic EPS (TTM)−1.28USD
Founded2017
CEODavid Campbell
Websitejanuxrx.com
About
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−6,465.00%
−4,865.00%
−3,265.00%
−1,665.00%
−65.00%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−30.00 M
−20.00 M
−10.00 M
0.00
10.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
JANX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company